More than sixty years after chemist Calvin Stevens first synthesized ketamine in the laboratories of Parke-Davis—originally seeking a safer, short-acting anesthetic—the molecule has undergone a profound metamorphosis. It has migrated from the surgical suite to the psychiatric clinic, shedding its reputation as a mere sedative to become a cornerstone of modern neuropharmacology. Today, its S-enantiomer, esketamine, marketed by Johnson & Johnson as Spravato, stands as a blockbuster therapeutic for treatment-resistant depression (TRD).
As of early 2025, the drug has entered a new phase of its commercial and clinical life, now approved by the FDA as the only monotherapy for TRD. With annual global sales reaching $1.7 billion in 2025 and projections climbing toward $2.3 billion for 2026, Spravato is no longer a niche intervention. It is a high-stakes, high-growth pillar of the psychiatric market. However, as the drug’s adoption increases, so does the scrutiny regarding its efficacy, long-term impact, and the medical community’s definition of "remission."
A Chronology of Clinical Transformation
The path to Spravato’s current dominance was neither linear nor uncontroversial. The journey began with the original ketamine molecule, but the development of the S-enantiomer allowed for a more potent, refined approach to targeting the N-methyl-D-aspartate (NMDA) receptor.
- March 2019: The FDA grants approval for esketamine nasal spray as an adjunct treatment for adults with treatment-resistant depression. At this stage, it was strictly a "second-line" add-on to traditional oral antidepressants.
- The Early Launch Period: Following the 2019 rollout, the drug experienced a quiet, measured adoption period. Clinicians remained cautious, largely due to the stringent Risk Evaluation and Mitigation Strategy (REMS) requirements, which necessitate supervised administration in a clinical setting with a two-hour post-dose monitoring window.
- January 2025: A significant regulatory pivot occurs. The FDA clears Spravato as the first and only monotherapy for adults with TRD, broadening its utility and removing the prerequisite of concurrent oral antidepressant use.
- Present Day: With the expanded indication, the focus has shifted from mere "symptom reduction" to "sustained clinical remission," a metric that is becoming the central narrative for Johnson & Johnson’s growth strategy.
The Magnitude of the Challenge: Defining TRD
To understand the market potential and the clinical necessity of Spravato, one must look at the sheer scale of the depression crisis in the United States. According to data from the National Institute of Mental Health (NIMH), an estimated 21 million U.S. adults experienced at least one major depressive episode in 2021, accounting for 8.3% of the adult population.
Of the 8.9 million adults currently receiving pharmacological treatment for major depression, roughly one-third—approximately 2.8 million individuals—fail to achieve an adequate response to standard oral antidepressants. This failure to respond to two or more different classes of medication is the clinical threshold for a diagnosis of treatment-resistant depression.
Dr. Rakesh Jain, MD, MPH, a clinical professor of psychiatry at the Texas Tech University School of Medicine, Permian Basin, frames the problem as a public health failure. "There are millions upon millions of patients, some of them your friends and mine, some of them your family members, who are being treated for depression and are simply not in remission," Jain notes. For these individuals, the standard "trial-and-error" approach of swapping SSRIs or SNRIs often results in diminishing returns, as evidenced by the seminal STAR*D trial, where remission rates plummeted to below 15% after the second treatment failure.
Supporting Data: The Case for Remission
The recent data presented at the Psych Congress Elevate meeting represents an attempt by Johnson & Johnson to consolidate the case for esketamine by focusing on remission rates rather than mere symptom improvement.
The analysis, led by Dr. Jain, synthesized data from six distinct clinical trials, ranging from short-term placebo-controlled studies to long-term open-label extensions. The benchmark for success in this analysis was the Montgomery-Åsberg Depression Rating Scale (MADRS), a 10-item clinician-rated instrument. While a score of 7 to 19 typically indicates mild depression, the study focused on a "remission" threshold of 10 or below.
Key Findings from the Compiled Analysis:
- Short-Term Efficacy: In the TRANSFORM-2 trial, Spravato plus an oral antidepressant showed a 42.6% remission rate at four weeks, compared to 24.0% for the placebo-plus-antidepressant group.
- Monotherapy Performance: In the TRD4005 trial, monotherapy doses showed remission rates of 13.9% and 21.5% at week four, significantly outpacing the 6.5% rate seen in the placebo group.
- Long-Term Durability: Perhaps the most compelling data emerged from the open-label extension studies (ESCAPE-LTE, SUSTAIN-2, and SUSTAIN-3). Patients who continued treatment exhibited remission rates of 49.3% at one year, 78.2% at 2.5 years, and 43.2% at the 5.5-year follow-up mark.
While these numbers appear impressive, the analysis carries an important caveat: it is descriptive. It lacks a formal meta-analysis and relies on varying trial designs, which limits direct head-to-head statistical comparisons.
Professional Skepticism and the "Remission" Debate
Despite the optimism expressed by proponents like Dr. Jain, the clinical community remains divided. The reception of esketamine varies significantly across global health authorities.
The 2022 VA/DoD clinical guidelines for depression offer only a "weak for" recommendation, citing low-quality evidence and concerns regarding the feasibility of the intensive monitoring requirements. Meanwhile, the UK’s National Institute for Health and Care Excellence (NICE) declined to recommend the drug for routine NHS use in 2022, arguing that the economic and clinical evidence did not justify the high cost—a decision made prior to the drug’s approval as a monotherapy.
Critiques have also appeared in the American Journal of Psychiatry. In 2025, a systematic review by Fountoulakis et al. highlighted that, in the short term, the effect sizes for esketamine as an add-on therapy are relatively modest—often comparable to the effects seen in atypical antipsychotic augmentation. Furthermore, some researchers, including Baylor psychiatrists Sanjay Mathew and Nicholas Murphy, have questioned the necessity of long-term maintenance, noting that the phase 3 program did not definitively establish that patients require years of continued treatment.
Implications for the Future of Psychiatry
The success of Spravato rests on two pillars: the clinical data and the "psychology of the clinician." Dr. Jain argues that the primary barrier to wider utilization is not just cost or logistics, but professional inertia.
"Psychiatry is slow to change," Jain admits. "Many clinicians have heard of Spravato but are hesitant, not for any particular reason, but that is simply the nature of the field."
The Roadblocks to Adoption
- Logistical Burdens: The REMS program is a major hurdle. The requirement for a certified site and a two-hour monitoring period demands significant administrative and physical space, which many private psychiatric practices cannot accommodate.
- Safety Concerns: The potential for dissociation, sedation, and the risk of abuse remains a focal point for cautious practitioners.
- The "Early Intervention" Shift: The central goal of J&J’s current marketing and education push is to convince psychiatrists to move away from the "wait-and-see" approach. The data presented at Psych Congress Elevate is specifically designed to persuade clinicians that by waiting through multiple failed oral antidepressant trials, they are depriving patients of a potential path to remission that could be initiated much earlier.
A Shifting Paradigm
As Spravato continues its ascent toward $2.3 billion in annual revenue, the conversation is moving beyond the drug itself and toward a fundamental redesign of how we treat depression. The integration of "procedural" psychiatry—where the patient is brought into a clinic for a specific, time-bound intervention—marks a departure from the traditional model of "take-a-pill-at-home" psychiatry.
Whether this trend will ultimately yield a new standard of care or whether it will be tempered by continued debates over long-term efficacy and cost-effectiveness remains to be seen. For now, the data presented by researchers like Dr. Jain serves as a powerful call to action, pushing the psychiatric field to reconcile its historical skepticism with the mounting pressure to offer better outcomes to those who have yet to find relief from the cycle of chronic depression.
In the final analysis, Spravato is more than a chemical compound; it is a catalyst for a broader discussion on what it truly means to achieve—and hold—remission in the face of one of the world’s most persistent and debilitating health challenges.
About the Author
